Interplay between hypercholesterolaemia and inflammation in atherosclerosis: Translating experimental targets into clinical practice

José Tuñón, Magnus Bäck, Lina Badimón, Marie Luce Bochaton-Piallat, Bertrand Cariou, Mat J. Daemen, Jesus Egido, Paul C. Evans, Sheila E. Francis, Daniel F.J. Ketelhuth, Esther Lutgens, Christian M. Matter, Claudia Monaco, Sabine Steffens, Erik Stroes, Cécile Vindis, Christian Weber, Imo E. Hoefer

Research output: Contribution to journalArticlepeer-review


Dyslipidaemia and inflammation are closely interconnected in their contribution to atherosclerosis. In fact, low-density lipoprotein (LDL)-lowering drugs have anti-inflammatory effects. The Canakinumab Antiinflammatory Thrombosis Outcome Study (CANTOS) has shown that interleukin (IL)-1β blockade reduces the incidence of cardiovascular events in patients with previous myocardial infarction and C-reactive protein levels >2 mg/L. These data confirm the connection between lipids and inflammation, as lipids activate the Nod-like receptor protein 3 inflammasome that leads to IL-1β activation. LDL-lowering drugs are the foundation of cardiovascular prevention. Now, the CANTOS trial demonstrates that combining them with IL-1β blockade further decreases the incidence of cardiovascular events. However, both therapies are not at the same level, given the large evidence showing that LDL-lowering drugs reduce cardiovascular risk as opposed to only one randomized trial of IL-1β blockade. In addition, IL-1β blockade has only been studied in patients with C-reactive protein >2 mg/L, while the benefit of LDL-lowering is not restricted to these patients. Also, lipid-lowering drugs are not harmful even at very low ranges of LDL, while anti-inflammatory therapies may confer a higher risk of developing fatal infections and sepsis. In the future, more clinical trials are needed to explore whether targeting other inflammatory molecules, both related and unrelated to the IL-1β pathway, reduces the cardiovascular risk. In this regard, the ongoing trials with methotrexate and colchicine may clarify whether the cardiovascular benefit of IL-1β blockade extends to other anti-inflammatory mechanisms. A positive result would represent a major change in the future treatment of atherosclerosis.

Original languageEnglish (US)
Pages (from-to)948-955
Number of pages8
JournalEuropean Journal of Preventive Cardiology
Issue number9
StatePublished - Jun 1 2018


  • Lipids
  • atherosclerosis
  • canakinumab
  • immune response
  • inflammation
  • interleukin-1β

ASJC Scopus subject areas

  • Epidemiology
  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Interplay between hypercholesterolaemia and inflammation in atherosclerosis: Translating experimental targets into clinical practice'. Together they form a unique fingerprint.

Cite this